Lumos Diagnostics (ASX: LDX) Expands FebriDx to 141 WellStreet Clinics

Lumos Diagnostics Holdings will expand use of its FebriDx point-of-care test to another 97 WellStreet Urgent Care locations, taking adoption across the US operator’s network to 141 clinics in Ohio, Georgia and Michigan.

The rollout will lift the total number of US sites using FebriDx to 365 once implemented. Lumos and WellStreet also anticipate extending the test to all of WellStreet’s more than 200 locations by 31 December 2026, although that broader rollout remains an expectation rather than a confirmed deployment.

WellStreet’s network handles more than 1 million acute respiratory presentations annually. It estimates that such infections account for 70% to 80% of patient visits during the cold and flu season, giving Lumos a sizeable potential testing pool within the expanded network.

The announcement did not disclose pricing, expected test volumes or the potential revenue contribution from WellStreet, leaving the financial impact of the rollout unquantified.

From pilot site to standard protocol

FebriDx uses a fingerstick blood sample to help clinicians distinguish between bacterial and non-bacterial infections. Under WellStreet’s protocol, the rapid test will be offered to patients presenting with acute respiratory infection symptoms, with results available before the treating provider enters the examination room.

The expansion follows a staged evaluation that began with a single-site pilot announced in October 2025 through WellStreet’s joint venture with Piedmont Healthcare in Atlanta. After FebriDx received a waiver under the US Clinical Laboratory Improvement Amendments framework from the US Food and Drug Administration in March 2026, the program was extended to another 43 clinics in Michigan and Georgia.

The latest decision adds 97 locations and embeds FebriDx within WellStreet’s standardised triage procedures across the 141 participating centres. That progression is commercially relevant for Lumos because it moves the product beyond a limited pilot into broader routine clinical use within a large urgent care operator.

WellStreet reports improved antibiotic stewardship

WellStreet Senior Medical Officer Brian S. Bobb said the test had supported clinicians during the pilot and produced measurable improvements in antibiotic stewardship.

“FebriDx has become a valuable tool to our clinicians during this pilot period, augmenting their ability to appropriately diagnose and treat patients with acute respiratory illnesses,” Bobb said.

The company did not provide supporting data for the reported improvement. However, WellStreet’s decision to widen adoption provides operational validation following the pilot, while the planned network-wide expansion offers Lumos a further potential source of US demand if completed.